The American Psychiatric Association (APA) has updated its Privacy Policy and Terms of Use, including with new information specifically addressed to individuals in the European Economic Area. As described in the Privacy Policy and Terms of Use, this website utilizes cookies, including for the purpose of offering an optimal online experience and services tailored to your preferences.

Please read the entire Privacy Policy and Terms of Use. By closing this message, browsing this website, continuing the navigation, or otherwise continuing to use the APA's websites, you confirm that you understand and accept the terms of the Privacy Policy and Terms of Use, including the utilization of cookies.

×
CorrectionFull Access

Correction

Published Online:

In the article “A Nationwide Cohort Study of Oral and Depot Antipsychotics After First Hospitalization for Schizophrenia,” by Jari Tiihonen et al. (Original article: Am J Psychiatry 2011; 168:603–609), in the first sentence of the second paragraph of the Results section, the mean follow-up period of 2 years (5,221 person-years) reflects the potential time frame for discontinuation of medication. However, the actual mean follow-up time in the analysis of all-cause discontinuation was 0.5 years, and the number of person-years was 809, since follow-up for any given patient stopped after discontinuation of medication. The actual numbers of person-years for each antipsychotic are listed in Figure S1 in the online data supplement.